4836 results for "*oma"

in 11.42 milliseconds.

• Evolution of an adenomacarcinoma in response to selection by targeted kinase inhibitors

  Background - Adenocarcinomas of the tongue are rare and represent the minority (20-25%) of salivary gland tumors affecting the tongue. We investigated the utility of massively parallel sequencing to characterize an adenocarcinoma of the tongue, before and after treatment. Results - In the pre-treatment tumor we identified 7,629 genes within regions of copy number gain. 1,078 genes exhibited increased expression relative to the blood and unrelated tumors and four genes contained somatic protein-coding mutations. Our analysis suggested the tumor cells were driven by the RET oncogene. Genes whose protein products are targeted by the RET inhibitors sunitinib and sorafenib correlated with being amplified and or highly expressed. Consistent with our observations administration of sunitinib was associated with stable disease lasting 4 months, after which the lung lesions began to grow. Administration of sorafenib and sulindac provided disease stabilization for an additional 3 months after which the cancer progressed and new lesions appeared. A recurring metastasis possessed 7,288 genes within copy number amplicons, 385 genes exhibiting increased expression relative to other tumours and 9 new somatic protein coding mutations. The observed mutations and amplif ications were consistent with therapeutic resistance arising through activation of the MAPK and AKT pathways. Conclusions - We conclude that complete genomic characterization of a rare tumour has the potential to aid in clinical decision making and identifying therapeutic approaches where no established treatment protocols exist. These results also provide direct in-vivo genomic evidence for mutational evolution within a tumor under drug selection and potential mechanisms of drug resistance accrual.

  Study EGAS00000000074

• ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas

  We have sequenced the whole transcriptomes of 18 ovarian clear-cell carcinomas and 1 ovarian clear-cell carcinoma cell line and found somatic mutations in ARID1A (the AT-rich interactive domain 1A [SWI-like] gene) in 6 of the samples. ARID1A encodes BAF250a, a key component of the SWI–SNF chromatin remodeling complex. We sequenced ARID1A in an additional 210 ovarian carcinomas and a second ovarian clear-cell carcinoma cell line and measured BAF250a expression by means of immunohistochemical analysis in an additional 455 ovarian carcinomas

  Study EGAS00000000075

• Osteosarcoma_Sequencing

  Genomic libraries (500 bps) will be generated from total genomic DNA derived from 25 osetocarcinoma samples and subjected to total of three lanes of 37 bp paired end sequencing on the llumina GA per sample. Paired reads will be mapped to build 37 of the human reference genome to facilitate the generation of genome wide copy number information, and the identification of novel rearranged cancer genes and gene fusions.

  Study EGAS00001000013

• Familial Melanoma Sequencing

  In this experiment we have sequenced the exome of 15 individuals from eight families who have familial melanoma. By sequencing the exome we hope to be able to identify new genes that are associated with this disease.

  Study EGAS00001000017

• ADCC_Rearrangement_Screen

  Genomic libraries (500 bps) will be generated from total genomic DNA derived from 25 adenoid cystic carcinoma samples and subjected to total of eight lanes of 37 bp, paired end sequencing on the llumina GA. Paired reads will be mapped to build 37 of the human reference genome to facilitate the generation of genome wide copy number information, and the identification of novel rearranged cancer genes and gene fusions.

  Study EGAS00001000030

• Container Study for ICGC Malignant Lymphoma Master Study (MMML)

  Master Container Study for Malignant Lymphoma data (ICGC - Germany)

  Study EGAS00001001600

• MD Anderson Melanoma Genomic Medicine

  Dac EGAC00001000324

• Data Access Commitee epithelioid sarcoma

  Dac EGAC00001003250

• A Comprehensive Catalogue of Somatic Mutations from a Human Cancer Genome

  We have carried out complete sequencing of the genome of the human male maligant melanoma cell line COLO-829 using the Illumina Genome Analyzer II. We generated a sequencing library with a median insert size of ~200 bp following random fragmentation and gel fractionation of the genomic DNA. We sequenced 75 bases from both ends of these templates to cover the COLO-829 genome to an average depth of more than 40x. We have carried out purity-filtering (PF) to remove mixed reads, where two or more different template molecules are close enough on the surface of the flow-cell to form a mixed or overlapping cluster. No other filtering of the data has been carried out prior to submission. We have also submitted sequence data for a lymphoblastoid control cell line COLO-829BL from the same individual.

  Study EGAS00000000052

• Kaposi_sarcoma_exome

  Agilent whole exome hybridisation capture will be performed on genomic DNA derived from Kaposi sarcoma cancer and matched normal DNA from the same patients. Next Generation sequencing will be performed on the resulting exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes

  Study EGAS00001000032

• Chondrosarcoma_Targeted_Sequencing_Study

  This Study uses a focused bait pull down library method to target findings of Chondrosarcoma whole genome and whole exome sequencing studies in order to validate findings. This method will also be used on a larger set of tumour only samples in order to find precedence of these finding in a larger set of patients.

  Study EGAS00001000277

• A MITF germline mutation predisposes to melanoma and renal cell carcinoma

  Study EGAS00000000048

• Leiomyosarcoma Data Access Committee

  Dac EGAC00001000415

• Melanoma RNA Seq Data commitee

  Dac EGAC00001002928

• Hodgkin's Lymphoma WGS Commitee

  Dac EGAC00001003015

• Melanoma Institute Australia Data Access Committee

  Dac EGAC00001003075

• MGA-NUTM1 fusion in high grade spindle cell sarcoma

  Dac EGAC00001001074

• Primary plasma cell leukemia (pPCL) samples were sequenced using the Nimblegen MedExome hybridization capture to detect translocations, copy number changes, and mutations in 20 pPCL samples and patient matched controls.

  Primary plasma cell leukemia (pPCL) is a rare malignancy related to multiple myeloma. Here we have assembled 20 patient samples and performed whole exome sequencing to determine the differences between multiple myeloma and pPCL. CD138+ cells were purified from bone marrow aspirates from patients with pPCL. Control cells were obtained from CD34+ stem cell harvests or CD3+ T cells. DNA was extracted and processed using the HyperPlus library prep kit (KAPA Biosystems) and sequenced using 75 bp paired end reads on an Illumina NextSeq500.

  Study EGAS00001003104

• Bolleboom-Gao peri-tumoral snRNA-seq glioblastoma dataset 2022/A - Data Access Committee

  Dac EGAC00001003049

• Genetic alterations in metastatic uveal melanoma

  Study EGAS00001003303

• Berlin Neuroblastoma Dataset DAC

  Dac EGAC00001003082

• Berlin Neuroblastoma Dataset DAC

  Dac EGAC00001003112

• Analysis of the genomic landscape of chemoresistant multiple myeloma

  Study EGAS00001003709

• Genetic modification of primary human B cells to model high-grade lymphoma

  Study EGAS00001003560

• Myeloma RNAseq

  Study EGAS00001003999

• Neuroblastoma Data Access Committee

  Dac EGAC00001000085

• Osteosarcoma Data Access Commitee

  Dac EGAC00001001080

• Berlin Neuroblastoma Liquid Biopsy Data Access Committee

  Dac EGAC00001003314

• Carcinosarcoma Cohort from NHS Greater Glasgow, Clyde Biorepository, and Imperial College London

  Dac EGAC00001003299

• Data Access Commitee for the project : Methylome profiling of human mesenchymal chondrosarcoma

  Dac EGAC00001003217

• University of Miami Myeloma Genomics Lab

  Dac EGAC00001003337

• Data Access Commitee of mantle cell lymphoma

  Dac EGAC00001001119

• High-grade serous ovarian carcinoma organoids as models of chromosomal instability Data Access Committee

  Dac EGAC00001003204

• MD Anderson Lymphoma & Myeloma Data Access Committee

  Dac EGAC00001002990

• Microenvironment in lymphoma pathogenesis and therapy - DAC

  Dac EGAC00001003228

• MOMA Data Access Committee

  Dac EGAC00001000145

• Sarcoma Data Access Committee

  Dac EGAC00001003226

• Berlin Neuroblastoma Dataset DAC

  Dac EGAC00001003101

• Berlin Neuroblastoma Dataset DAC

  Dac EGAC00001003104

• Neuroblastoma DAC

  Dac EGAC00001002585

• CDH Asian Head and Neck Angiosarcoma

  Dac EGAC00001003145

• Data Access Commitee for single-cell analysis of multiple myeloma and precursors

  Dac EGAC00001002920

• Gene expression profile of mesothelial-derived carcinoma-associated fibroblasts Data Access Commitee

  Dac EGAC00001001267

• AMC Neuroblastoma Study

  Dac EGAC00001000047

• PUMCH-ICT Hepatocellular Carcinoma Study Data Access Committee

  Dac EGAC00001000070

• Barts Cancer Institute - Follicular Lymphoma Whole Genome Sequencing Project Data Access Committee

  Dac EGAC00001000086

• Glioma Genomics Committee

  Dac EGAC00001000153

• Study of pediatric hepatocellular carcinoma with BSEP deficiency

  Dac EGAC00001000191

• DAC for seminoma genomic data

  Dac EGAC00001000231

• Carcinosarcoma Data Access Committee

  Dac EGAC00001000234

• JHMI Cholangiocarcinoma DAC

  Dac EGAC00001000276

• This DAC is to control access to data contained within dataset EGAS00001001147, for Myeloma XI clinical trial patients.

  Dac EGAC00001000307

• Institut Curie Neuroblastoma data access Committee

  Dac EGAC00001000319

• TRACERx esophageal adenocarcinoma

  Dac EGAC00001000340

• Glioma exome array DAC

  Dac EGAC00001000345

• Somatotropinoma Data Access Committee

  Dac EGAC00001000353

• Pancreatic Adenocarcinoma Data Access Committee

  Dac EGAC00001000358

• Relapsed and Primary Neuroblastoma DAC

  Dac EGAC00001000373

• Basal Cell Carcinoma HTS data

  Dac EGAC00001000405

• DATA ACCESS AGREEMENT CGNT- GROUP COMMITTEE for project "Exome sequencing of 22 Pheochromocytoma/paraganglioma tumors" at Gothenburg University.

  Dac EGAC00001000411

• The Dutch retinoblastoma research team from the VU University medical center

  Dac EGAC00001000431

• DAC for Dependency of Transcriptional circuit of glioblastoma-associated macrophages that drive mesenchymal differentiation

  Dac EGAC00001000441

• DAC for esophageal squamous cell carcinoma genomic data

  Dac EGAC00001000444

• Wellcome Trust Sanger Institute Data Sharing Policy for Trachoma GWAS

  Dac EGAC00001000489

• DAC for Melanoma Exome Dataset for Identification of Mutated Epitopes

  Dac EGAC00001000546

• DAC Genomic and transcriptomic profiling of signalling networks in follicular lymphoma

  Dac EGAC00001000577

• High-grade meningioma DAC

  Dac EGAC00001000625

• DAC for Mesothelioma Genomics Study

  Dac EGAC00001000615

• PUMCH-ICT Hepatocellular Carcinoma Study Data Access Committee

  Dac EGAC00001000627

• PUMCH-ICT Hepatocellular Carcinoma Study Data Access Committee

  Dac EGAC00001000628

• Multiple myeloma ChIP-seq DAC

  Dac EGAC00001000647

• Data access committee for the pseudomyxoma peritonei exome sequencing vcf-files

  Dac EGAC00001000649

• Clonal evolution study of Intrahepatic cholangiocarcinoma: 69 PDPCs and 6 tissues.

  Dac EGAC00001000718

• ZKJ - Highly differentiated rhabdomyosarcoma

  Dac EGAC00001000722

• DAC for MOMA, Short QT Exome data

  Dac EGAC00001000730

• This committee is composed on individuals who have access to the data corresponding to this project: Gut microbiome modulates response to anti PD-1 immunotherapy in melanoma patients

  Dac EGAC00001000758

• Data Access Committee for the UCSF Chordoid Glioma of the Third Ventricle Genome Project Dataset

  Dac EGAC00001000776

• RNA Seq fastq files generated for the "Proteogenomic landscape of medulloblastoma subgroups"

  Dac EGAC00001000792

• Whole genome sequencing of Hepatoblastoma Data Access Committee

  Dac EGAC00001000798

• UT MD Anderson Cancer Center Department of Genomic Medicine Lipoasarcoma Data Access Committee

  Dac EGAC00001000821

• Myeloma Research Laboratory, University of Adelaide and South Australian Health and Medical Research Institute

  Dac EGAC00001000849

• UCSF Sebaceous Carcinoma DAC for review of sequence data release from manuscript in Nature Communications, based in the UCSF Departments of Dermatology and Pathology

  Dac EGAC00001000850

• DAC for Genomic landscpae of Chordoid Glioma study

  Dac EGAC00001000906

• Data Access Committee for the Medulloblastoma Host Genome Study

  Dac EGAC00001000910

• Sahlgrenska Translational Melanoma Group Data Access Commitee

  Dac EGAC00001000915

• Synovial Sarcoma Data Access Committee

  Dac EGAC00001000921

• The molecular landscape of glioma in patients with Neurofibromatosis 1

  Dac EGAC00001001004

• Capture Hi-C on Hodgkin lymphoma DAC

  Dac EGAC00001001006

• ChIP-seq on Hodgkin lymphoma DAC

  Dac EGAC00001001007

• Wargo Group Data Access Committee for Neodjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma

  Dac EGAC00001001008

• Sahlgrenska Translational Melanoma Group

  Dac EGAC00001001085

• Single-cell RNA-seq of immune cells from Melanoma tumors (Li et al, 2018) - DAC

  Dac EGAC00001001089

• DAC for Peritoneal Mesothelioma sequencing study (LAGA-VPC)

  Dac EGAC00001001093

• Glioma GWAS summary statistics DAC

  Dac EGAC00001001116

• DAC for study EGAS00001003438: Clonal Heterogeneity in Glioblastoma

  Dac EGAC00001001118

• Somatotropinoma Data Access Committee

  Dac EGAC00001001135

• Genomic stratification and liquid biopsy in a rare adrenocortical carcinoma (ACC) case, with dual lung metastases

  Dac EGAC00001001138

• DAC for WGS data Romanians and Roma/Rroma (Romania)

  Dac EGAC00001001184

• Immune and Metabolic Features of Brain Metastases Melanoma (Cancer Discovery) Data Access Committee

  Dac EGAC00001001216

• Infant Glioma RNASeq Data Access Committee

  Dac EGAC00001001241